[dropcap letter="I"]
mportant news in the Iberian subsidiary of Leo Pharma in the year of its 25th anniversary. The pharmaceutical company, one of the world leaders in medical dermatology, has just appointed Nuno Bras as general manager in Spain and Portugal. The Portuguese executive will lead in these two countries the new 2030 strategic plan launched by the multinational with the aim of becoming "the leading supplier laboratory of innovative medicines that help treat skin diseases."
[subscribe_newsletter_esp]
Bras has worked at Leo Pharma since 2011 and was the general manager of the company in Portugal and in the Nordic Countries. Since 2019 he held the position of vice president of the laboratory in France, Canada, and Benelux. He replaces Paolo Cionini, who will now lead Leo Pharma in the so-called Eucan area, which includes a dozen countries, from Canada to New Zealand, including Switzerland, Slovakia, Greece, and Australia.
"Spain is, together with Portugal, one of the strategic markets for Leo Pharma in Europe," highlights Nuno Bras, who holds a degree in Pharmacy and is a specialist in bio-dermatology.
The new general manager arrives in the year of celebration of the 25th anniversary of the Iberian subsidiary, which is headquartered in Barcelona, a city that has always been closely linked to the pharmaceutical industry. The change in the management team has coincided with the relocation of the company's headquarters from Torre Mapfre to new offices located on Via Laietana.
Leo Pharma has also incorporated in the last year a new communications director, Montse Carbó, from the GBfoods group.
The Danish laboratory, founded in 1908, belongs entirely to the Leo Foundation, which reinvests all profits into R&D&I of new medicines. The company is one of the leaders in the treatment of thrombosis and operates in more than 130 countries, with a turnover of about 1.5 billion euros. In 2019 the pharmaceutical company gave a strong boost to its business by acquiring Bayer's prescription dermatology division.